Effect of Atorvastatin on Vascular Inflammation in Type 2 Diabetes

• Status: Withdrawn
• Trial end date: 2012-03-01
• Target enrollment: 0
• Participant gender: All

Summary

Type 2 diabetes mellitus significantly increases the risk for the development of atherosclerosis. Recently, atherosclerosis imaging with 18F-FDG PET (18F-Fluorodeoxyglucose Positron Emission Tomography) is useful for tracking inflammation within plaque and monitoring the response to drug therapy

The purpose of this study is to determine whether FDG-PET is capable of detecting atherosclerotic vascular inflammation and monitoring the early effects of statins in type 2 diabetic patients. The usefulness of FDG-PET in risk stratification is also investigated.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Korea University
• Treatments: Atorvastatin; Atorvastatin Calcium

Criteria

Inclusion Criteria:

• Type 2 diabetic patients who are aged 35 to 80 year-old

Exclusion Criteria:

• Insulin use

• Patients who receive any dyslipidaemia under medications (including statins) in recent one year

• Women of child-bearing potential are excluded (i.e. menopausal women or post-hysterectomy women are included in this study) due to radiation exposure in this study

• Active inflammatory diseases

• Vasculitis, symptomatic coronary artery disease, symptomatic cerebrovascular diseases

• Significant concomitant disease such as active infection, malignancy, hepatic or renal dysfunction at the time of enrollment (i.e. T-Bil > 3 mg/dl，ALT > 2.5 times the upper limit of normal range and Creatinine > 2 mg/dl in our hospital)